Abstract
791 Phase 2 study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have